Express hundreds of antibodies in parallel to find your best candidate
Selecting the right lead requires more than binding data. We guarantee a minimum of 1 mg per antibody to unlock in-depth early developability assessment.
Go beyond a single ELISA readout: test each candidate across a wider panel of assays, simultaneously.
Identify liabilities before they become problems. 1 mg is enough to run stability and aggregation tests from your very first screening round.
Get all the data you need in one pass, no intermediate scale-up required to complete your characterization.
Why the guaranteed quantity matters
| ProteoGenix HTP service | Market average for HTP services | |
|---|---|---|
| Purified quantity per candidate | 1 mg guaranteed, every candidate | Typically 50 µg to a few hundred µg by default; 1 mg often only available as a paid, higher-volume tier |
| Early developability assessment | 1 mg provides enough material to test purity, binding, stability, aggregation and developability liabilities, as your program requires | Purity, concentration, and one binding readout (e.g. ELISA) |
| Assays possible with the material received | Full multi-criteria comparison across candidates | Often limited to a single readout unless additional volume is purchased |
| Risk of selecting the wrong lead | Low: candidates compared on multiple criteria before scale-up | Higher: selection often based on binding alone, with developability liabilities surfacing later |
Characterization
Keep candidate selection aligned with the properties that matter for your program rather than relying on a single screening readout.
Purity and structural integrity
Binding activity and functional validation
Early developability assessment
Identity and post-translational modifications
Use our price calculator to estimate the cost of your high-throughput antibody production project based on your antibody format, number of candidates, required quantity and optional characterization services.
ProteoGenix produces a broad range of antibody formats in CHO cells so you can screen the molecule that matches your application without changing CRO between formats.
Full length
IgG
Full-length recombinant antibodies for screening, binding and functional workflows.
Fragments
Fab
Fab production for programs requiring antigen-binding fragments.
Fragments
scFv
Single-chain variable fragments for compact recombinant antibody formats.
Single-domain
VHH
Single-domain antibody formats for discovery and screening workflows.
Complex formats
Bispecific antibodies
Specify your desired architecture; our team can discuss construct requirements before production.
Custom
Other formats
IgA, IgM, IgE, Fc-fusions and other custom formats can be discussed with the scientific team.
Delivery : Full report + purified samples shipped.
Your HTP candidates are expressed on XtenCHO™ Race, ProteoGenix’s in-house transient CHO platform, developed and validated for demanding antibody projects.
High-productivity CHO expression
Internal benchmarks show 1.5- to 9.7-fold improvements in yield, depending on the antibody, with yields up to 1.8 g/L.
Competitive cost as you scale: higher titers and reduced culture volumes support efficient HTP and larger production workflows.
Scientific evidence
Li Y, Wu J, Li J, et al. Monoclonal antibody against canine distemper virus H protein potently neutralizes the giant panda-derived strain. AMB Express. 2026;16:5. view publication
Bonduelle O, Colin L, Della Pia EA, et al. Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation. Front Immunol. 2022;13:848571. view publication
Ball JA, et al. Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning. Front Immunol. 2026;16:1726449. view publication
Renn A, et al. Heterologous saRNA prime – multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV. Sci Rep. 2026;16:14565.
Because ProteoGenix runs the same CHO system at every scale, your lead sequences progress directly from HTP to larger production. The antibody characterized during screening is the same molecule produced at scale.
mg → gram
Transient antibody production services
gram → kilogram
Stable cell line development service
Case reports
18 antibody variants rapidly expressed with >90% purity, streamlining candidate selection and accelerating development.
10.63mg recombinant antibodies delivered at >90% purity, meeting preclinical quality and yield standards.
